DK2094086T3 - Indgivelse in vivo af dobbeltstrenget rna til en målcelle - Google Patents

Indgivelse in vivo af dobbeltstrenget rna til en målcelle

Info

Publication number
DK2094086T3
DK2094086T3 DK07873598.2T DK07873598T DK2094086T3 DK 2094086 T3 DK2094086 T3 DK 2094086T3 DK 07873598 T DK07873598 T DK 07873598T DK 2094086 T3 DK2094086 T3 DK 2094086T3
Authority
DK
Denmark
Prior art keywords
submitting
rna
vivo
double
strength
Prior art date
Application number
DK07873598.2T
Other languages
English (en)
Inventor
Catherine J Pachuk
Original Assignee
Veritas Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Bio LLC filed Critical Veritas Bio LLC
Application granted granted Critical
Publication of DK2094086T3 publication Critical patent/DK2094086T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07873598.2T 2006-11-08 2007-11-06 Indgivelse in vivo af dobbeltstrenget rna til en målcelle DK2094086T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85750106P 2006-11-08 2006-11-08
US90701407P 2007-03-16 2007-03-16
US95661007P 2007-08-17 2007-08-17
US97469507P 2007-09-24 2007-09-24
US97895007P 2007-10-10 2007-10-10
PCT/US2007/083805 WO2008118212A2 (en) 2006-11-08 2007-11-06 In vivo delivery of double stranded rna to a target cell

Publications (1)

Publication Number Publication Date
DK2094086T3 true DK2094086T3 (da) 2013-11-25

Family

ID=39789159

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07873598.2T DK2094086T3 (da) 2006-11-08 2007-11-06 Indgivelse in vivo af dobbeltstrenget rna til en målcelle
DK12189351.5T DK2548438T3 (da) 2006-11-08 2007-11-06 In vivo indgivelse af dobbeltstrenget rna til en celle

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12189351.5T DK2548438T3 (da) 2006-11-08 2007-11-06 In vivo indgivelse af dobbeltstrenget rna til en celle

Country Status (5)

Country Link
US (5) US8524679B2 (da)
EP (3) EP2094086B1 (da)
DK (2) DK2094086T3 (da)
ES (1) ES2434169T3 (da)
WO (1) WO2008118212A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2094086T3 (da) * 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
ES2549190T3 (es) * 2010-03-01 2015-10-23 Inovio Pharmaceuticals, Inc. Aplicador y dispositivo de electroporación de múltiples capas de tejido
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
DK2561073T3 (da) 2010-04-23 2016-12-12 Univ Massachusetts Aav-vektorer målrettet mod centralnervesystemet og fremgangsmåder til anvendelse deraf
CA3050894C (en) 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
US8518409B2 (en) 2010-05-31 2013-08-27 Imperium Biotechnologies, Inc. System for selective cell treatment using ideotypically modulated pharmacoeffectors
US8383405B2 (en) * 2010-05-31 2013-02-26 Imperium Biotechnologies, Inc. Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
WO2012145624A2 (en) 2011-04-21 2012-10-26 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
KR20140068000A (ko) 2011-06-15 2014-06-05 크론테크 파마 아베 주사 바늘 및 장치
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
BR112016020688B1 (pt) 2014-03-09 2024-01-30 The Trustees Of The University Of Pennsylvania Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
JP6756700B2 (ja) 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ 筋萎縮性側索硬化症を処置するためのｒＡＡＶベースの組成物および方法
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
WO2016054557A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Novel high efficiency library-identified aav vectors
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
AU2016291813B2 (en) 2015-07-14 2022-09-01 Transalgae Israel Ltd. Transgenic microalgae and use thereof as a feed for delivery of interfering RNA molecules
WO2017070516A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
EP3364997B1 (en) 2015-10-22 2024-01-17 University of Massachusetts Aspartoacylase gene therapy in the treatment of canavan disease
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
JP2019515654A (ja) 2016-03-16 2019-06-13 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
EP3440210A4 (en) 2016-04-05 2019-11-27 University of Massachusetts COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (ko) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
EP3618839A4 (en) * 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018264996A1 (en) 2017-05-09 2019-12-05 University Of Massachusetts Methods of treating Amyotrophic Lateral Sclerosis (ALS)
CN111194210B (zh) * 2017-08-04 2024-02-20 俄亥俄州创新基金会 一种利用纳米电穿孔和其他非内吞的细胞转染制备治疗性外泌体的方法
CN118006607A (zh) 2017-09-22 2024-05-10 马萨诸塞大学 Sod1双表达载体及其用途
EP3684377B1 (en) 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
US11491483B2 (en) 2018-02-15 2022-11-08 Ohio State Innovation Foundation Microfluidic devices and methods for high throughput electroporation
WO2019236995A1 (en) 2018-06-08 2019-12-12 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
JP7898376B2 (ja) * 2019-08-06 2026-07-31 オハイオ・ステイト・イノベーション・ファウンデーション 治療用細胞外小胞
TWI811688B (zh) * 2020-05-27 2023-08-11 中央研究院 單核球專一性之適體及其增強藥物輸送至癌症之用途
WO2026163125A1 (en) 2025-01-29 2026-08-06 Symbiotica Therapeutics S.R.L. A genetically modified eukaryotic microalga and injectable composition for symbiotic therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359100A (en) * 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US7148205B2 (en) * 1995-12-13 2006-12-12 Mirus Bio Corporation Intravascular delivery of non-viral nucleic acid
US6379966B2 (en) * 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US20040259828A1 (en) 1995-12-13 2004-12-23 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6217900B1 (en) * 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7642248B2 (en) 1999-11-05 2010-01-05 Roche Madison Inc Devices and processes for distribution of genetic material to mammalian limb
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US8202846B2 (en) * 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
CA2443393A1 (en) * 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
JP2005528091A (ja) * 2002-03-14 2005-09-22 アノシス・インコーポレーテッド Ｔ細胞由来小胞の機能化、および免疫原性医薬組成物を製造するためのその使用
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050239728A1 (en) 2002-07-31 2005-10-27 Pachuk Catherine J Double stranded rna structures and constructs, and methods for generating and using the same
ATE395102T1 (de) 2002-10-15 2008-05-15 Novo Nordisk As In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
ATE554185T1 (de) 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
US20050130919A1 (en) * 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
EP1709194A4 (en) * 2003-12-17 2007-07-25 Univ Columbia DISTRIBUTION OF DNA OR RNA VIA NEXI OF HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SIRNA
EP2169072A1 (en) 2004-08-23 2010-03-31 Alnylam Pharmaceuticals, Inc Multiple RNA polymerase III promoter expression constructs
CN101370927A (zh) * 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
US7605251B2 (en) * 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
DK2094086T3 (da) * 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle

Also Published As

Publication number Publication date
EP2094086B1 (en) 2013-08-28
US8524679B2 (en) 2013-09-03
US20130344133A1 (en) 2013-12-26
EP2548438A1 (en) 2013-01-23
ES2434169T3 (es) 2013-12-13
EP2094086A2 (en) 2009-09-02
EP2548438B1 (en) 2015-08-05
EP2094086A4 (en) 2011-06-22
US20140349390A1 (en) 2014-11-27
EP2799547B1 (en) 2016-12-21
WO2008118212A2 (en) 2008-10-02
EP2799547A1 (en) 2014-11-05
US20140348882A1 (en) 2014-11-27
US20150297625A9 (en) 2015-10-22
DK2548438T3 (da) 2015-10-19
US20100323001A1 (en) 2010-12-23
US20130302403A1 (en) 2013-11-14
WO2008118212A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
EP2094086A4 (en) IN VIVO ADMINISTRATION OF DOUBLE-STRANDED RNA TO A TARGET CELL
EP2470642A4 (en) CELL EXPANSION METHOD
PL2634243T3 (pl) Ulepszony sposób hodowli komórkowej
SI2240572T1 (sl) Uporaba RNA za reprogramiranje somatskih celic
DK2043972T3 (da) Biodieselproduktion under anvendelse af kompositkatalysatorer
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK2574677T3 (da) Fremgangsmåder til celledyrkning
ATE530578T1 (de) Antikörper gegen il-17a
DK2279263T3 (da) Rnase-h-baserede assays med anvendelse af modificerede rna-monomerer
DK2048955T3 (da) Målrettet gen-tilførsel til dendrit-cellevaccination
DK2046941T4 (da) Forbedret tilslutning til engangsbioreaktorbeholder
DK2195450T3 (da) Fremgangsmåder til anvendelse af mirna til detektion af in vivo celledød
DK2104737T3 (da) Funktioner og formål for let-7 mikro-RNAer
CR10693A (es) Enantiomerically pure phosphoindoles as hiv inhibitors
DK2527471T3 (da) Diagnosticering af cancer ved anvendelse af genomsekvensering
DE112007001371B8 (de) Brennstoffzelle
DE112007002407B8 (de) Brennstoffzelle
BRPI0816956A2 (pt) Célula de combustível
EP2212405A4 (en) METHOD OF RELATING DIESEL FUEL
DE602008000048D1 (de) Brennstoffzelle
EP2128242A4 (en) CELL CULTURE MODULE
EP2167688A4 (en) TARGETED CELL DEATH
EP2316491A4 (en) CELL PROLIFERATION INHIBITORS
DK2081675T3 (da) Syntese af biodiesel
EP2318508A4 (en) DETERMINATION OF RNA INTEGRITY